SCHEMBL20965335

SCHEMBL20965335

COc1ccccc1N1CCN(C(=O)c2ccccc2OCc2c(C)noc2C)CC1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.66
NPC1 O15118 1/20 0.66
KMT2A Q03164 4/20 0.58
TSHR P16473 4/20 0.58
MEN1 O00255 3/20 0.58
AKR1C3 P42330 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 2/20 0.57
GAA P10253 1/20 0.57
MAPT P10636 2/20 0.57
HTT P42858 1/20 0.57
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
MAPK1 P28482 1/20 0.54
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19747273 0.91 SMN1; SMN2 (0.71) L3MBTL1NPC1KMT2ATSHRMEN1
SCHEMBL20965411 0.90 L3MBTL1 (0.66) L3MBTL1NPC1KMT2ATSHRMEN1
SCHEMBL20964625 0.90 L3MBTL1 (0.66) L3MBTL1NPC1KMT2ATSHRMEN1
SCHEMBL20965449 0.90 L3MBTL1 (0.67) L3MBTL1NPC1KMT2ATSHRMEN1
SCHEMBL20965433 0.89 L3MBTL1 (0.66) L3MBTL1NPC1KMT2ATSHRMEN1
SCHEMBL20964721 0.87 L3MBTL1 (0.77) L3MBTL1NPC1KMT2ATSHRMEN1
SCHEMBL20964668 0.87 SMN1; SMN2 (0.72) L3MBTL1NPC1KMT2ATSHRAKR1C3
SCHEMBL20964608 0.86 L3MBTL1 (0.61) L3MBTL1NPC1KMT2ATSHRMEN1
SCHEMBL20964544 0.86 L3MBTL1 (0.68) L3MBTL1NPC1KMT2ATSHRAKR1C3
SCHEMBL20965305 0.85 L3MBTL1 (0.66) L3MBTL1NPC1KMT2ATSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 L3MBTL1 4755/4885NPC1 11/4885KMT2A 4728/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 L3MBTL1 4517/4885NPC1 2196/4885KMT2A 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.